Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerResumen de Investigación
Analyzed using Evidence Intelligence™
GZR18 Improves Glycemic Control in Type 2 Diabetes
Última actualización 12 de septiembre de 2026
Key finding
HbA1c decreased by 1.32% for GZR18 versus 0.86% for placebo in Part A.
The study evaluated GZR18, a long-acting GLP-1 analog, and found it significantly reduced HbA1c levels in adults with type 2 diabetes.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
High Risk
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
The study evaluated GZR18, a long-acting GLP-1 analog, and found it significantly reduced HbA1c levels in adults with type 2 diabetes.
Clinical relevance
This study highlights the potential of GZR18 as a safe and effective treatment option for adults with type 2 diabetes, addressing a critical need for effective glycemic control. The significant reductions in HbA1c levels suggest that GZR18 could improve long-term health outcomes for patients managing diabetes.
Keep in mind
The study's sample size and demographic diversity are not specified. Long-term effects of GZR18 were not assessed. The trial duration may not reflect chronic treatment outcomes.
Published in
Referencia de la Revista
Publication details and source links for this paper.
Ming L, Xuhong W, Meizi L, et al. GZR18, a Long-Acting GLP-1 Analog, Reduces HbA1c in Adults with Type 2 Diabetes. Cell Reports Medicine. 2026;7(7):102874. doi:10.1016/j.xcrm.2026.102874
Efectos Principales
GZR18 reduced HbA1c by 1.32% compared to placebo in Part A.
GZR18 reduced HbA1c by 1.81% compared to placebo in Part B.
Improvements in body weight were observed with GZR18.
GZR18 was associated with mostly mild-to-moderate gastrointestinal adverse events.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to GZR18 and Body weight, Gastrointestinal disorders incidence, HbA1c, and 2 more.
This study contributes evidence to
Primary intervention
GZR18
Primary outcomes
- Body weight
- Gastrointestinal disorders incidence
- HbA1c
Evidence topics
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
5
Evidence pairs
5
Relationships
2
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 68
2
Related topics
5
Evidence pairs
979
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 5 evidence relationships
- Includes primary outcome data
- Linked to 2 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Agrega evidencia relacionada a tu Evidence Tracker
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Tema de evidencia
HbA1c Reduction
matched_outcome
Evidencia relacionada
Tema de evidencia
Weight Loss
Guardar evidencia
Core evidence
Study findings
The primary outcomes reported in this study.
Gastrointestinal disorders incidence
GZR18 → Gastrointestinal disorders incidence
GZR18 → Gastrointestinal disorders incidence
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerSerious perinatal adverse events
GZR18 → Serious perinatal adverse events
GZR18 → Serious perinatal adverse events
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
La Evidencia Sugiere
- GZR18 decreased HbA1c by 1.32% in Part A and 1.81% in Part B.
- No severe hypoglycemia events were reported during the trial.
- GZR18 was well tolerated with mild-to-moderate gastrointestinal side effects.
A quién se aplica
- Adults diagnosed with type 2 diabetes.
- Individuals seeking new treatment options for glycemic control.
Tener en Cuenta
- The findings may not apply to populations outside the study's demographic.
- The study did not evaluate the long-term safety and efficacy of GZR18.
- Further research is needed to confirm these results in larger, more diverse populations.
Entre Líneas
- The study's sample size and demographic diversity are not specified.
- Long-term effects of GZR18 were not assessed.
- The trial duration may not reflect chronic treatment outcomes.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GZR18 and Body Weight, GZR18 and Gastrointestinal Adverse Events.
Relaciones de evidencia relacionadas
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
GZR18 → Body Weight
Medications
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
View evidenceMedications
GZR18 → Gastrointestinal Adverse Events
Medications
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
View evidenceIncluido en estas colecciones de evidencia
Curated evidence collections and hubs this study is part of.
Body Weight Evidence Hub
All studies measuring Body Weight
1 studies
outcome_hubMeasures Body Weight as a key outcome.
Gastrointestinal Adverse Events Evidence Hub
All studies measuring Gastrointestinal Adverse Events
1 studies
outcome_hubMeasures Gastrointestinal Adverse Events as a key outcome.
GZR18 Evidence Hub
All studies on GZR18
1 studies
intervention_hubContributes to GZR18 evidence base.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explora más en Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on GZR18 and Body weight
Intervention: GZR18Outcome: Body weight
1 results
All studies on GZR18 and Gastrointestinal disorders incidence
Intervention: GZR18Outcome: Gastrointestinal disorders incidence
1 results
All studies on GZR18
Intervention: GZR18
1 results
All studies measuring Body weight
Outcome: Body weight
1 results
All studies measuring Gastrointestinal disorders incidence
Outcome: Gastrointestinal disorders incidence
1 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does GZR18 affect body weight?
Emerging Evidence
GZR18 appears to affect body weight.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Body weight
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does GZR18 lower HbA1c?
Emerging Evidence
GZR18 appears to lower HbA1c.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does GZR18 reduce gastrointestinal disorders incidence?
Emerging Evidence
Current evidence does not show a clear reduction in gastrointestinal disorders incidence with GZR18.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Gastrointestinal disorders incidence
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does GZR18 affect serious perinatal adverse events?
Emerging Evidence
Current evidence does not show a clear effect of GZR18 on serious perinatal adverse events.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Serious perinatal adverse events
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Switching to tirzepatide improves glycemic control and weight in type 2 diabetesCombination Therapy Reduces HbA1c and Weight in Type 2 DiabetesDietary interventions improve glycemic control in pre-diabetic patientsInsulin glargine plus metformin and glimepiride improves glycemic control in type 2 diabetes.Semaglutide improves glycemic control more than insulin aspart in type 2 diabetes
Sin anuncios. Sin rastreo.
Centrada en la evidencia, no en la publicidad.
Segura y privada
Tus datos siempre están protegidos.
Siempre al día
Se agregan nuevos estudios todos los días.